0 -monoxime is a derivative of the bis-indole alkaloid indirubin, an active ingredient of a traditional Chinese medical preparation that exhibits anti-inflammatory and anti-leukemic activities. Indirubin-3 0 -monoxime is mainly recognized as an inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3. It inhibits proliferation of cultured cells, mainly through arresting the cells in the G1/S or G2/M phase of the cell cycle. Here, we report that indirubin-3 0 -monoxime is able to inhibit proliferation of NIH/3T3 cells by specifically inhibiting autophosphorylation of fibroblast growth factor receptor 1 (FGFR1), blocking in this way the receptormediated cell signaling. Indirubin-3 0 -monoxime inhibits the activity of FGFR1 at a concentration lower than that required for inhibition of phosphorylation of CDK2 and retinoblastoma protein and cell proliferation stimulated by fetal calf serum. The ability of indirubin-3 0 -monoxime to inhibit FGFR1 signaling was similar to that of the FGFR1 inhibitor SU5402. In addition, we found that indirubin-3 0 -monoxime activates long-term p38 mitogen-activated protein kinase activity, which stimulates extracellular signal-regulated kinase 1/2 in a way unrelated to the activity of FGFR1. Furthermore, we show that indirubin-3 0 -monoxime can inhibit proliferation of the myeloid leukemia cell line KG-1a through inhibition of the activity of the FGFR1 tyrosine kinase. The data presented here demonstrate previously unknown activities of indirubin-3 0 -monoxime that may have clinical implications.
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Introduction
Fibroblast growth factor (FGF)-mediated signaling is an evolutionarily conserved signaling module operative in invertebrates and vertebrates (Itoh and Ornitz, 2004) . The biological action of FGFs is exerted through binding to high-affinity cell surface FGF receptors (FGFR). The FGFR family consists of five related genes. FGFR1-4 have a conserved overall structure consisting of an extracellular ligand-binding domain, a single transmembrane spanning region and a wellconserved split tyrosine kinase domain. Additional diversity among members of the family is generated by mechanisms based on alternative splicing of the FGFR mRNA and alternative promoter activity resulting in receptor isoforms (Dailey et al., 2005) .
Binding of the FGF ligand to FGFR results in receptor dimerization and autophosphorylation at tyrosine residues in the intracellular part of the receptor. Ligand-induced dimerization and autophosphorylation of tyrosines in the activating loop of the tyrosine kinase are key events that lead to an increased activity of the receptor kinase. Other phosphotyrosines serve as binding sites for recruitment and activation of downstream signaling molecules (Eswarakumar et al., 2005) . It has recently been shown that tyrosines in FGFR1 are autophosphorylated in a sequential and strictly ordered manner (Furdui et al., 2006) . In this way, the activated-FGFR transduces signals by activating different signaling cascades including Ras/mitogen-activated protein kinase (MAPK), PI3K/Akt, PLCg/PKC and p38 MAPK (Boilly et al., 2000) . Thereby, autophosphorylation of the receptor regulates diverse cellular processes such as cell proliferation, differentiation or migration. Inappropriate expression and/or activation of FGFRs participate in some pathological conditions, particularly neoplasia, diabetic retinopathy, rheumatoid arthritis and atherosclerosis (Powers et al., 2000) .
The bis-indole alkaloid indirubin is an active ingredient of a traditional Chinese medical preparation that exhibits anti-inflammatory activity and antileukemic activity against myelocytic leukemia (Hoessel et al., 1999) . Indirubin and particularly indirubin derivatives such as indirubin-3 0 -monoxime and indirubin-5-sulfonate, which have low toxicity, have been considered as anticancer agents (Hoessel et al., 1999) . Indirubin and its derivatives have been described as selective inhibitors of cyclin-dependent kinases (CDKs) such as CDK1/ cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/ p25 (Hoessel et al., 1999; Davies et al., 2001; Marko et al., 2001; Jautelat et al., 2005) . It has been reported that these compounds are able to inhibit the proliferation of a variety of cultured cell types by a block in the G1/S or the G2/M phase of the cell cycle. It has also been shown that the indirubin derivatives indirubin-5-sulfonate and indirubin-3 0 -monoxime bind to the CDK2 adenosine triphosphate-binding site and in this way inhibit the kinase activity (Hoessel et al., 1999; Davies et al., 2001) . Furthermore, indirubin-3 0 -monoxime, but not indirubin, was able to inhibit CDK9 in a cell-free kinase assay and to inhibit replication of HIV-1 in blood mononuclear cells and macrophages (Heredia et al., 2005) . Additionally, it was recently reported that indirubin derivatives were able to block Stat3 signaling by inhibiting the Src kinase activity and in this way induce apoptosis in human cancer cells (Nam et al., 2005) , and also, bind to and inhibit glycogen synthetase kinase-3 (Leclerc et al., 2001; Polychronopoulos et al., 2004) , aryl hydrocarbon receptor (Adachi et al., 2001) , muscle glycogen phosphorylase b (Kosmopoulou et al., 2004) and c-Jun NH2-terminal kinase (JNK) (Xie et al., 2004) . More recently, indirubin-3 0 -monoxime was found to inhibit the activation of nuclear factor-kB resulting in enhancement of apoptosis induced by tumor necrosis factors in human leukemic cells (Sethi et al., 2006) .
Here, we show that the indirubin derivative indirubin-3 0 -monoxime is able to inhibit specifically autophosphorylation of the FGFR1 kinase in NIH/3T3 and KG-1a cells, blocking in this way the receptor tyrosine kinase-mediated cell signaling and cell growth. We find that indirubin-3 0 -monoxime is at least as efficient as the previously described specific-FGFR1 inhibitor SU5402 (Mohammadi et al., 1997) , and inhibition of FGFR1 occurs at a lower concentration of indirubin-3 0 -monoxime than that required to inhibit CDK2. We also report that in contrast to SU5402, indirubin-3 0 -monoxime activates p38 MAPK and extracellular signalregulated kinase (ERK)1/2 in an FGFR1-independent manner.
Results

Different ability of indirubin-3
0 -monoxime to inhibit DNA synthesis in NIH/3T3 cells when stimulated with FGF-1 or fetal calf serum (FCS) Indirubin and derivatives such as indirubin-3 0 -monoxime have been described as inhibitors of cell proliferation and as selective inhibitors of CDKs. We tested the ability of indirubin-3 0 -monoxime to inhibit DNA synthesis in NIH/3T3 cells stimulated with FCS or with FGF-1. NIH/3T3 cells that had been serum-starved for 24 h were stimulated with 50 ng/ml FGF-1 in the presence of 10 U/ml heparin or with 10% FCS and at the same time treated with increasing concentrations of indirubin-3 0 -monoxime. Indirubin-3 0 -monoxime inhibited the FGF-1-induced [ 3 H]thymidine incorporation at a concentration of 5-10 mM, with a IC 50 value at approximately 2.5 mM (Figure 1a ). On the other hand, when the cells were stimulated with FCS the inhibitory concentration of indirubin-3 0 -monoxime was 20-40 mM and IC 50 value around 10 mM. Thus, cells treated only with FGF-1 are more sensitive to indirubin-3 0 -monoxime than cells treated with FCS. Many factors in FCS can stimulate cell proliferation through activation of CDKs. The higher sensitivity of FGF-1-stimulated cells to indirubin-3 0 -monoxime suggested that one or several components in the FGF responsive pathway could be more sensitive targets to this drug than the CDKs.
NIH/3T3 cells express FGFR1. Therefore, for comparison, we also tested the ability of the FGFR1 inhibitor SU5402 to inhibit DNA synthesis. The results showed that SU5402 inhibited [
3 H]thymidine incorporation in NIH/3T3 cells at a concentration of approximately 20 mM (IC 50 >5 mM) in cells treated with 50 ng/ml FGF-1, but inhibited [ 3 H]thymidine incorporation only slightly in cells treated with 10% FCS (Figure 1b ). This is consistent with the reported ability of SU5402 to specifically inhibit FGFR1 at 10-20 mM (Mohammadi et al., 1997) .
To test for adverse effects of indirubin-3 0 -monoxime and SU5402, we tested the toxic effect of the drugs by measuring alterations in the level of protein synthesis. Cells were treated with increasing concentrations of the drugs overnight and the ability of the cells to incorporate [
3 H]leucine into trichloroacetic acid (TCA)-precipitable material was used to estimate the rate of protein synthesis. The IC 50 value for inhibition of [ 3 H]leucine incorporation by indirubin-3 0 -monoxime was found to be around 40-60 mM, similarly for cell treated with 50 ng/ml FGF-1 or with 10% FCS (Figure 1c ). Below 20 mM the inhibitory effect of indirubin-3 0 -monoxime was very low. For SU5402, the IC 50 value for inhibition of [ 3 H]leucine incorporation was found to be approximately 60 mM after overnight treatment of cells incubated either with FGF-1 or with FCS ( Figure 1d ). No obvious change in morphology of the cells was observed after overnight incubation with 20 mM indirubin-3 0 -monoxime or 20 mM SU5402 in the presence of FGF-1 (Figure 1e) . Thus, at non-toxic concentrations that do not inhibit FCS-induced passage of the cells through the cell cycle, both indirubin-3 0 -monoxime and SU5402 can inhibit FGF-1-induced DNA synthesis in NIH3T3 cells.
Ability of indirubin-3
0 -monoxime to inhibit in vivo autophosphorylation of FGFR1 We tested indirubin-3 0 -monoxime for its ability to inhibit the protein tyrosine kinase activity of FGFR1 in NIH/3T3 cells under FGF-1 stimuli and compared it to the inhibitory activity of SU5402. The cells were pretreated with the drugs for 15 min at 371C and then stimulated with 50 ng/ml FGF-1 and 10 U/ml heparin for 30 min at 371C. The treated cells were lysed and FGFR1 was immunoprecipitated with antibodies to FGFR1 and immunoblotted with monoclonal antibody 
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0 -monoxime inhibits FGFR1 Y Zhen et al against phosphorylated FGFR as described in Materials and methods. As shown in Figure 2a , autophosphorylation of FGFR1 induced by FGF-1 was inhibited at approximately 5-10 mM indirubin-3 0 -monoxime (lanes 5 and 6) and, consistent with previous reports (Mohammadi et al., 1997) , at 10-20 mM of SU5402 (lanes 14 and 15). In addition, we investigated the specificity of the effect by checking the ability of indirubin-3 0 -monoxime to inhibit autophosphorylation of epidermal growth factor receptor (EGFR) in HeLa cells. As shown in Figure 2b the drug had no detectable inhibitory effect on the phosphorylation of the tyrosine kinase of EGFR within a range of concentration of 1-40 mM. These results suggest that indirubin-3 0 -monoxime specifically inhibits the autophosphorylation of FGFR1.
0 -monoxime does not affect FGF-1 binding to low-and high-affinity receptors or internalization of the ligand-receptor complex It has been shown that formation of stable complexes consisting of FGF, FGFR and heparan sulfate proteoglycans (HSPG, also referred to as low-affinity FGFR) is required to induce a mitogenic signal by the growth factor (Lin et al., 1999; Ornitz, 2000) . Moreover, endocytic uptake of the FGF-FGFR complex seems to be significant for induction of DNA synthesis (Zhan et al., 1993; Imamura et al., 1994) . Therefore, we wanted to test for the possibility that the observed inhibitory effect of indirubin-3 0 -monoxime was due to an effect on binding of FGF-1 to its low-and high-affinity receptors or due to an inhibitory effect on FGF-FGFR-HSPG internalization. We investigated the ability of FGF-1 to bind to heparin immobilized on Sepharose beads in the presence of increasing concentrations of indirubin-3 0 -monoxime. Figure 3a shows that the compound does not interfere with binding of FGF-1 to heparin for a range of tested concentrations.
Then we tested whether indirubin-3 0 -monoxime could interfere with binding of FGF-1 to FGFR1 on the cell surface of NIH/3T3 cell. We incubated NIH/3T3 cells with increasing amounts of 125 I-FGF-1 in the presence of 10 U/ml heparin, with or without 30 mM indirubin-3 0 -monoxime at 41C. The cells were then washed with 1 M NaCl in phosphate-buffered saline (PBS), which removes FGF-1 bound to cell-surface heparans but not FGF-1 bound to FGFR, before the cell associated 125 I-FGF-1 was quantitated. As seen in Figure 3b , there was no significant effect of the compound on the binding of the growth factor to cell surface FGFR. 
Inhibition of receptor-mediated signaling If indirubin-3
0 -monoxime blocks the activity of FGFR1 in living cells, this effect should be reflected in an inhibition of downstream signaling events at approximately the same range of inhibitor concentrations. We therefore investigated whether indirubin-3 0 -monoxime, in comparison to SU5402, is able to block cell signaling events known to be regulated by autophosphorylation of FGFR1.
Serum-starved NIH/3T3 cells were pretreated for 15 min with increasing concentrations of the drugs and then stimulated with 50 ng/ml FGF-1 and 10 U/ml heparin for 30 min. The cells were then lysed and the cell lysates were analysed by SDS-PAGE and immunoblotting (Figure 4) . First, we checked whether stimulation of the Ras/MAPK pathway was affected by using antibodies specific for phospho-FRS2 and phospho-ERK1/2. Phosphorylation of these proteins was inhibited at approximately the same concentrations of indirubin-3 0 -monoxime and SU5402 that were required to inhibit autophosphorylation of FGFR1, namely at 2.5-5 and 10-20 mM, respectively (Figure 4, lanes 4, 5 and 14, 15 ).
Next, we tested the activation of the PI3-kinase cascade, which leads to phosphorylation of Akt, and we tested the phosphorylated status of PLCg and Src. As shown in Figure 4 phosphorylation of Akt, PLCg and Src was inhibited by both drugs approximately at 2.5-5 mM.
We also looked at the phosphorylation of p38 MAPK and this was found to be slightly inhibited by 2.5-5 mM indirubin-3 0 -monoxime and similarly by 10 mM SU5402. However, at around 10-40 mM of indirubin-3 0 -monoxime the level of phosphorylated p38 MAPK was again substantially increased (lanes 6-8). This phenomenon was not observed for SU5402 treated cells. p38 MAPK is known to be activated by varies types of stress, and therefore, we also tested the activity of another stress-induced MAP kinase, JNK. As shown in Figure 4 this kinase was not activated under FGF-1 treatment (lanes 1, 2 and 9, 10), but at concentrations 20-40 mM of indirubin-3 0 -monoxime the level of phosphorylated JNK was dramatically increased (lanes 7 and 8). Treatment of the cells with SU5402 did not induce this effect.
The obtained data indicate that indirubin-3 0 -monoxime is able to block FGFR1-mediated signaling by inhibition of the activity of the receptor, similarly to the inhibitor SU5402. In addition, indirubin-3 0 -monoxime, but not SU5402, is able to activate the stress-induceable MAP kinases p38 and JNK.
Indirubin-3
0 -monoxime inhibits the cell-cycle regulatory apparatus at a higher concentration than that required to inhibit FGFR1 To examine whether indirubin-3 0 -monoxime preferentially inhibits the activity of FGFR1 over other kinases in living cells, we carried out experiments where NIH/3T3 cells were stimulated with FGF-1 or FCS and treated with a low or a high concentration of the drug.
Since inhibition of autophosphorylation of FGFR1 appeared at around 5 mM for indirubin-3 0 -monoxime and at around 20 mM for SU5402 we tested whether at these concentrations of the inhibitors NIH/3T3 cells could respond to increasing concentrations of the growth factor. When starved cells were treated with increasing amounts of FGF-1 in the presence of 5 mM indirubin-3 0 -monoxime the stimulatory response of the cells to FGF-1, measured by [ 3 H]thymidine incorporation, was almost completely inhibited even at 100 ng/ml FGF-1 (Figure 5a ). However, when treated with the same concentration of SU5402 the cells were still able to incorporate [ 3 H]thymidine at approximately 75% of the value reached by untreated cells. Thus, the observed differences between indirubin-3 0 -monoxime and SU5402 in their ability to inhibit FGFR1 in the FGFR1 phosphorylation assay (as shown in Figure 2 ), is reflected in DNA stimulation experiments.
When starved NIH/3T3 cells were stimulated with increasing concentrations of FCS and 5 mM indirubin-3 0 -monoxime, the [ 3 H]thymidine incorporation was not inhibited, indicating that at this concentration the cell-cycle regulatory machinery was unaffected Figure 5b ). Also, 20 mM SU5402 did not inhibit the DNA synthesis. But when the cells were treated with 20 mM indirubin-3 0 -monoxime the stimulation of DNA synthesis was strongly inhibited even at 10% FCS. This indicated that indirubin-3 0 -monoxime inhibits the cellcycle regulatory apparatus at a higher concentration than what is required to block autophosphorylation of FGFR1. To support this hypothesis further, we stimulated starved NIH/3T3 cells with increasing amounts of EGF, to omit activation of FGFR1, in the presence of 5 or 20 mM indirubin-3 0 -monoxime (Figure 5c ). Although the cells did not respond to EGF as strongly as to FGF-1, the obtained data clearly showed that 5 mM indirubin-3 0 -monoxime did not affect DNA synthesis induced by EGF, but 20 mM of indirubin-3 0 -monoxime efficiently blocked the response to EGF stimulation as it did for FCS stimulation.
To exclude the possibility that 5 mM of indirubin-3 0 -monoxime blocked the cell cycle of FCS-stimulated NIH/3T3 cells in the G2/M phase, and therefore, the treated cells were still able to induce DNA synthesis, we performed a cell proliferation assay on NIH/3T3 cells. The cells were under different stimuli in the absence or presence of indirubin-3 0 -monoxime or SU5420. As shown in Figure 5d , the number of NIH/ 3T3 cells after 4 days of incubation with 100 ng/ml FGF-1 increased around four times, approximately from 2.5 Â 10 4 to over 10 5 cells/sample (columns 1 and 2), whereas in the presence of 100 ng/ml FGF-1 and 5 mM indirubin-3 0 -monoxime the cell proliferation process was inhibited (column 3). A total of 5 mM of SU5402 only slightly reduced the proliferation of the cells (column 4), while 20 mM SU5402 effectively inhibited the cell proliferation process induced by FGF-1 (column 5). To omit FGFR1-dependent signaling, the assay was also performed in the presence of 10% FCS (columns 6-9). Under such conditions, 5 mM of indirubin-3 0 -monoxime or 20 mM of SU5402 did not inhibit proliferation (columns 7 and 8), whereas 20 mM of indirubin-3 0 -monoxime did (column 9). The use of EGF instead of FCS provided similar data. NIH/3T3 cells proliferated under EGF treatment without or with 5 mM indirubin-3 0 -monoxime (columns 10 and 11), but not in the presence of 20 mM indirubin-3 0 -monoxime (column 12).
The results indicate that under FGF-1 stimuli 5 mM of indirubin-3 0 -monoxime blocks the cell cycle by blocking the tyrosine kinase activity of FGFR1, and not by inducing a cell-cycle block in G2/M phase in an FGFRindependent manner, while at higher concentrations indirubin-3 0 -monoxime blocks the cell cycle by other mechanisms. 0 -monoxime (lanes 3-8) or SU5402 (lanes 11-16) for 15 min at 371C. Then the cells were left untreated (lanes 1 and 9) or stimulated with 50 ng/ml FGF-1 and 10 U/ml heparin for 30 min at 371C (lanes 2-8 and 10-16). The cells were subsequently lysed and analysed by immunoblotting with antibodies to phospho-FRS2, phospho-ERK1/2, total ERK1/2, phosphoAkt, total Akt, phospho-PLCg, phospho-Src, phospho-p38 MAPK, total p38 MAPK, phospho-JNK and total JNK1.
Inhibition of phosphorylation of Rb and CDK2 by indirubin-3 0 -monoxime The vast majority of polypeptide growth factors act during the G1 phase of the cell cycle promoting cells to progress through the G1/S phase transition. CDKs positively regulate the G1/S phase transition by phosphorylating the retinoblastoma protein (Rb), which leads to enhanced transcription of genes involved in the cell-cycle progression. Phosphorylation of Rb by CDKs is initiated in mid-G1 phase (Lundberg and Weinberg, 1998) .
To further test whether indirubin-3 0 -monoxime can affect cell-cycle regulated events we carried out in vivo Rb phosphorylation experiments. Serum-starved NIH/ 3T3 cells were treated with 50 ng/ml FGF-1 and 10 U/ml heparin or with 10% FCS, in the absence or presence of indirubin-3 0 -monoxime or SU5402 through increasing periods of time. After the treatment the cells were lysed and the cell lysates subjected to immunoblotting using antibodies against phosphorylated Rb (Figure 6 ). In cells treated with FGF-1 phosphorylated Rb is detectable after 6 h and increases during incubations for up to 22 h. However, when NIH/3T3 cells were treated with FGF-1 in the presence of 5 mM indirubin-3 0 -monoxime, phosphorylated Rb was undetectable. Treatment of cells with 5 mM SU5402 did not inhibit phosphorylation of Rb, but 20 mM of SU5402 completely inhibited phosphorylation of Rb. Under stimulation with FCS phosphorylated Rb was again detectable after 6 h and increased with longer incubations. In the presence of FCS, however, 5 mM indirubin-3 0 -monoxime did not inhibit the phosphorylation of Rb, but at a concentration of 20 mM the compound completely inhibited phosphorylation of Rb. About 20 mM of SU5402 did not block phosphorylation of Rb under FCS stimuli. Thus, whereas 5 mM of indirubin-3 0 -monoxime was sufficient to inhibit autophosphorylation of FGFR1 and phosphorylation of Rb in FGF-1-stimulated cells, 20 mM indirubin-3 0 -monoxime is required to inhibit phosphorylation of Rb in FCS-stimulated cells.
The activity of CDKs can be positively regulated by phosphorylation. It was shown that ERK1/2 could control the function of CDK2 by phosphorylation of the (Figure 7b ), 5 mM indirubin-3 0 -monoxime did not inhibit the phosphorylation of CDK2 (lane 2), but 20 mM indirubin-3 0 -monoxime did (lane 3). This set of data provide evidence that indirubin-3 0 -monoxime is able to inhibit in vivo phosphorylation of CDK2, but does so at a higher concentration than that required to block autophosphorylation of FGFR1.
0 -monoxime induces sustained activity of p38 MAPK Since we observed a stimulatory effect of 20 mM indirubin-3 0 -monoxime on the activity of p38 MAPK as well as JNK in NIH/3T3 after 30 min of treatment (as shown in Figure 4) , we investigated the activity of these kinases after longer periods of treatment. As shown in Figure 8a , when cells had been treated with indirubin-3 0 -monoxime for 5 h the level of phosphorylated p38 MAPK was increased already at 2.5 mM of indirubin-3 0 -monoxime (lane 2) and increased further for up to 20 mM indirubin-3 0 -monoxime (lane 5). The level of phosphorylated p38 MAPK was unchanged throughout the incubation period when cells were treated with SU5402 (lanes 6-10). After stripping, the membrane was reprobed with antibodies against phosphorylated ERK1/2. The results showed an increased level of phospho-ERK1/2, in a concentration-dependent manner, for cells treated with indirubin-3 0 -monoxime, but not SU5402. This suggested that the increased level of activated p38 MAPK might regulate the activity of ERK1/2. To investigate this further, we carried out experiments with FGF-1 stimulation for 5 h in the presence of 20 mM of the p38 MAPK inhibitor SB203580. As shown in Figure 8b , indirubin-3 0 -monoxime did not increase the level of phosphorylated ERK1/2 in the presence of SB203580. On the other hand, Figure 8c shows that SB203580 as such did not inhibit activation of ERK1/2 stimulated by FGF-1 in NIH/3T3 cells. These data indicate that under treatment of cells with indirubin-3 0 -monoxime p38 MAPK is activated and the activated p38 MAPK induces activation of ERK1/2.
We also tested whether the activity of JNK was increased after 5 h treatment with indirubin-3 0 -monoxime or with SU5402 ( Figure 8a ) and found that, in contrast to p38 MAPK and ERK1/2, the activity of JNK was not increased at this time point.
0 -monoxime inhibits proliferation of the myeloid leukemia cell line KG-1a by inhibiting the tyrosine kinase of FGFR1 To investigate whether indirubin-3 0 -monoxime has the potential to inhibit growth of FGFR-dependent cancers we used the KG-1a cell line. The KG-1 and KG-1a cell lines are developed from human acute myeloid leukemia Indirubin-3 0 -monoxime inhibits FGFR1 Y Zhen et al (AML) and as the result of a chromosomal rearrangement they express an FGFR1OP2-FGFR1 fusion protein. This protein consists of an oligomerizing domain fused to the tyrosine kinase domain of FGFR1, which is constitutively active and essential for proliferation of KG-1 cells (Popovici et al., 1999; Guasch et al., 2001; Gu et al., 2006) .
We measured the effect of indirubin-3 0 -monoxime and SU5402 on the growth of KG-1a cells, and as a control K562 cells, which are leukemia cells that do not express FGFR1. As shown in Figure 9a , the growth of KG-1a cells was significantly inhibited by 5 mM indirubin-3 0 -monoxime. Also SU5402 inhibited the growth of KG-1a cells, although 20 mM SU5402 was required to achieve an effect similar to that of 5 mM indirubin-3 0 -monoxime. The growth of K562 cells was not significantly inhibited by SU5402 or 5 mM indirubin-3 0 -monoxime, but was inhibited by 20 mM of indirubin-3 0 -monoxime, which is expected to block CDKs. Since indirubine-3 0 -monoxime stimulated p38 MAPK in NIH/3T3 cells we also tested whether 5 mM indirubin-3 0 -monoxime could inhibit growth of KG-1a cells in the presence of the p38 MAPK inhibitor SB203580. This gave a similar inhibition of growth as indirubin-3 0 -monoxime alone, indicating that the growth inhibitory effect of 5 mM indirubin-3 0 -monoxime on KG-1a cells is not due to activation of p38 MAPK, but is due to inhibition of the tyrosine kinase activity of the FGFR1OP2-FGFR1-fusion protein.
To test further whether 5 mM indirubin-3 0 -monoxime is able to inhibit the autophosphorylation of FGFR1OP2-FGFR1 and in this way inhibit activation Figure 9b , 5 mM indirubin-3 0 -monoxime inhibited the phosphorylation of FGFR1OP2-FGFR1, which in the western blot is indicated by a protein of approximately, 75 kD recognized by antibodies specific for FGFR1. About 5 mM indirubin-3 0 -monoxime also inhibited the phosphorylation of ERK1/ 2, PLCg, STAT1 and STAT3 in KG-1a cells. Previously, certain indirubin deratives were reported to inhibit phosphorylation of STAT3 by inhibiting an upstream kinase, Src (Nam et al., 2005) . However, 5 mM indirubin-3 0 -monoxime did not inhibit phosphorylation of Src in the KG-1a cells, indicating that phosphorylation of STAT3 in this case is a downstream event to phosphorylation of the FGFR1 kinase. SU5402 also inhibited phosphorylation of FGFR1OP2-FGFR1, ERK1/2, PLCg, STAT1 and STAT3 in KG-1a, but at 20 mM. In the case of K562 cells, treatment with neither of the drugs interfered with phosporylation of ERK1/2 (Figure 9b) . No FGFR1 or phosphorylated STAT3 could be detected in K562 (not shown). The obtained results provide further evidence that the growth inhibitory effect of 5 mM indirubin-3 0 -monoxime on KG-1a cells is due to specific inhibition of autophosphorylation of the FGFR1 tyrosine kinase domain in the FGFR1OP2-FGFR1 fusion protein.
Discussion
Indirubin-3 0 -monoxime is described as a potent inhibitor of CDKs, based on in vitro kinase assays, the crystal structure of CDK2-cyclin A/indirubin-5-sulfonate and studies performed on cell cultures (Hoessel et al., 1999; Davies et al., 2001) . Here, we provide evidence that indirubin-3 0 -monoxime is an efficient and specific inhibitor of the tyrosine kinase receptor FGFR1 at a concentration lower than that required for inhibition of CDKs. In our in vivo experimental systems, we found that 5 mM of indirubin-3 0 -monoxime was sufficient to block FGF-1-stimulated autophosphorylation of FGFR1 and cell proliferation in the NIH/3T3 cell line. About 5 mM of indirubin-3 0 -monoxime was also sufficient to inhibit the growth of KG-1a cells, which are cells derived from a human AML and whose growth depend on the activity of a fusion protein containing the FGFR1 tyrosine kinase domain. On the other hand 20 mM of indirubin-3 0 -monoxime was, required to inhibit phosphorylation of CDK2 and FCS-stimulated proliferation in NIH/3T3 cells and to inhibit growth of the leukemia cell line K562, which does not express FGFR1.
Indirubin-3 0 -monoxime appears to be at least as potent as the FGFR1 inhibitor SU5402, which in our experiments inhibited FGFR1 autophosphorylation and FGF/FGFR1-dependent cell proliferation at a concentration of 10-20 mM, consistent with previous findings (Mohammadi et al., 1997) . By western blot analysis, we found that indirubin-3 0 -monoxime and SU5402-inhibited autophosphorylation of FGFR1 and activation of downstream signaling effectors such as FRS2, ERK1/2, Akt, PLCg and Src, at approximately the same range of concentrations (2.5-10 mM). However, indirubin-3 0 -monoxime blocked stimulation of DNA synthesis and proliferation of NIH/3T3 cells with an IC 50 value of 2.5 mM when cells were under FGF-1 stimuli, whereas SU5402 blocked DNA synthesis with an IC 50 value of 10 mM.
The inability of 5 mM indirubin-3 0 -monoxime to inhibit stimulation of DNA synthesis and cell proliferation when cells were stimulated with 10% FCS or EGF makes it unlikely that other intracellular targets in addition to FGFR1 were blocked by 5 mM of indirubin-3 0 -monoxime. Thus, indirubin-3 0 -monoxime is a potent inhibitor of FGFR1.
Consistent with several previous reports that indirubin-3 0 -monoxime inhibits intracellular targets other than FGFR1 (Hoessel et al., 1999; Adachi et al., 2001; Leclerc et al., 2001; Xie et al., 2004; Sethi et al., 2006) , we found that in NIH/3T3 cells indirubin-3 0 -monoxime inhibited the phosphorylation of CDK2 and Rb, a CDK-regulated protein involved in regulation of cellcycle progression. However, the concentration of indirubin-3 0 -monoxime required to inhibit Rb and CDK2 phosphorylation was higher for FCS-stimulated cells than for FGF-1-stimulated cells, that is, 20 and 5 mM, respectively. Thus, in our experiments the CDKs seems to be about four times less sensitive to indirubin-3 0 -monoxime than FGFR1. Recently, it was reported that indirubin-3 0 -monoxime is able to inhibit the FGFR1 tyrosine kinase in an in vitro kinase assay with an IC 50 value of 0.74 mM while the IC 50 value for EGFR kinase was 102 mM (Ribas et al., 2006) . The IC 50 values for CDK2/CycA, CDK2/CycE and CDK1/CycB obtained in this in vitro kinase assay were 2.3, 2.2 and 20 mM respectively, that is, considerably higher than the IC 50 value for FGFR1. These data are in line with our in vivo studies.
While testing the ability of indirubin-3 0 -monoxime to inhibit FGFR1-mediating signaling, we noticed that the drug strongly stimulated phosphorylation of p38 MAPK and JNK. Activation of p38 MAPK was observed for 10-20 mM indirubin-3 0 -monoxime after a short (30 min) incubation time, but was evident already for 2.5-5 mM of indirubin-3 0 -monoxime after a longer (5 h) incubation time. While indirubin-3 0 -monoxime activated JNK at 10-20 mM after a short incubation time, we could not detect any increase in phosphorylated JNK after a longer incubation. The long-term activation of p38 MAPK by indirubin-3 0 -monoxime was probably not due to a general toxic effect since we found that the lowest amount of indirubin-3 0 -monoxime required to activate p38 MAPK was not toxic to the cells in an overnight experiment. Furthermore, SU5402, which had a similar toxicity to indirubin-3 0 -monoxime did not induce phosphorylation of p38 MAPK or JNK at all. These data support a specificity for the p38 MAPK pathway in the response to indirubin-3 0 -monoxime in NIH/3T3 cells.
In addition to activation of p38 MAPK, indirubin-3 0 -monoxime increased the level of phosphorylated ERK1/ Indirubin-3 0 -monoxime inhibits FGFR1 Y Zhen et al 2 in a dose-dependent manner. The phosphorylation of ERK1/2 was abolished when cells were treated with the inhibitor of p38 MAPK, SB203580, providing evidence that phosphorylation of p38 MAPK was an upstream event to phosphorylation of ERK1/2. Interestingly, while phosphorylation of ERK1/2 was observed after longer treatment of NIH/3T3 cells with only 2.5 mM indirubin-3 0 -monoxime, phosphorylation of ERK1/2 was undetectable after treatment with 20 mM indirubin-3 0 -monoxime for 30 min, even though phosphorylation of p38 MAPK at this time point was strongly increased.
The stimulatory effect of indirubin-3 0 -monoxime on p38 MAPK and ERK1/2 in these experiments must be unrelated to the activity of FGFR1, since this is efficiently blocked by the drug. The p38 MAPK pathway is known to be activated in response to chemical or inflammatory stress, whereas the ERK pathway is strongly activated by polypeptide growth factors through receptor tyrosine kinases (Roux and Blenis, 2004) . It is also known that p38 MAPK can be activated during different types of chemotherapy. Genotoxic drugs like cisplatin (Losa et al., 2003) as well as kinase inhibitors or ultraviolet and g-irradiation (Brancho et al., 2003; Losa et al., 2003) are recognized as agents able to stimulate p38 MAPK as well as JNK pathways (Bulavin et al., 1999; Sanchez-Prieto et al., 2000; Yu et al., 2000) . It was reported that stimulation of p38 MAPK and JNK activity is crucial for cisplatin-induced apoptosis (Benhar et al., 2001) , but specific inhibition of JNK or p38 MAPK suppresses the drug-induced cell death process (Tibbles and Woodgett, 1999) . Our results show that p38 MAPK, but not JNK, is long-term activated in the presence of indirubin-3 0 -monoxime and that activation of FGFR1 is not necessary for the activation of p38 MAPK in our experimental model. This suggests that the indirubin-3 0 -monoxime-induced activity of p38 MAPK is independent of upstream MAPK kinases, as was recently shown for anisomycin, sorbitol, peroxynitrite and genistein (Kang et al., 2006; Nguyen et al., 2006) . However, the exact mechanism by which indirubin-3 0 -monoxime activates p38 MAPK remains to be elucidated.
A distinctive stem cell myeloproliferative disorder that frequently transforms into AML is associated with chromosomal translocations that rearrange the FGFR1 gene at the 8p11-12 region. The translocations result in production of fusion proteins containing distinct Nterminal domains fused to the tyrosine kinase domain of FGFR1, which is constitutively active (MacDonald et al., 1995; Chaffanet et al., 1998; Popovici et al., 1999) . KG-1 and KG-1a are AML-derived cell lines that express an FGFR1OP2-FGFR1 fusion protein. It was shown that the growth of KG-1 cells depends on the activity of the FGFR1 kinase domain, as small interfering RNA (siRNA)-induced silencing of the FGFR1 fusion inhibited cell growth as well as phosphorylation of signaling molecules such as ERK1/2, PLCg and STAT3 (Gu et al., 2006) . In agreement with these observations, we found that 5 mM of indirubin-3 0 -monoxime, an amount sufficient to inhibit phosphorylation of the FGFR1OP2-FGFR1 kinase and downstream signaling molecules such as ERK1/2-, PLCg-, STAT1-and STAT3-inhibited proliferation of KG-1a cells. Although indirubin-3 0 -monoxime can activate p38 MAPK, and p38 MAPK has the potential to induce cell death by apoptosis (Tibbles and Woodgett, 1999; Benhar et al., 2001) , the growth inhibitory effect of indirubin-3 0 -monoxime on KG-1a cells was not related to activation of p38 MAPK since indirubin-3 0 -monoxime inhibited growth of KG-1a also in the presence of a p38 MAPK inhibitor. Thus, indirubin-3 0 -monoxime has the potential to inhibit growth of FGFR1-dependent cancer cells by directly targeting the FGFR1 tyrosine kinase. Using a higher concentration of indirubin-3 0 -monoxime (20 mM) sufficient to inhibit CDKs, the growth of K562 cells, which are leukemic cells that do not express FGFR1, was also inhibited, showing that indirubin-3 0 -monoxime can inhibit cancer cell growth through multiple molecular targets.
Because of their known anti-leukemic activity and low toxicity (Hoessel et al., 1999) , indirubin and its derivatives have for long been considered as anticancer agents. Initially, indirubin and its derivatives were described as inhibitors of CDKs; however, a number of different additional activities of the drugs have been discovered. As shown in this study, indirubin-3 0 -monoxime is a highly effective inhibitor of the tyrosine kinase activity of FGFR1, and furthermore, indirubin-3 0 -monoxime is able to elevate the level of active p38 MAPK and as a consequence of this increase the activity of ERK1/2. These findings shed light on the molecular mechanisms of action of indirubin-3 0 -monoxime and have potential clinical implications. (Mannheim, Germany) , phosphatase inhibitor cocktail, SB203580 and SU5402 were from (Calbiochem, La Jolla, CA, USA). Antibodies to phospho-ERK1/2 (mouse), ERK1/2 (rabbit), Akt (rabbit), phospho-Akt (rabbit), phospho-Src (rabbit), p38 MAPK (mouse), phospho-Rb (rabbit), phospho-CDK2 (rabbit), STAT3 (rabbit), phospho-STAT3 (rabbit) and phospho-FGFR (mouse) were from Cell Signaling Technology (Beverly, MA, USA). Anti-calreticulin (rabbit) was from Stressgen Biotechnologies (Victoria, BC, Canada). Anti-FGFR1 (rabbit), anti-PLCg (mouse), anti-phospho-PLCg (rabbit), antiphospho-JNK (mouse) and anti-JNK1 (rabbit) were from Santa Cruz, CA, USA). Anti-EGFR (mouse) and antiphospho-EGFR (mouse) were from Trans Laboratory (Lexinton, KY, USA) Anti-phospho-FRS2 (rabbit) was from Nordic Biosite (Ta¨by, Sweden), anti-phospho-p38 MAPK (rabbit) was from BD Biosciences Pharmingen (San Diego, CA, USA). Anti-mouse and anti-rabbit horse raddish peroxidase-linked secondary antibodies were from Jackson Immuno-Research Laboratories (West Grove, PA, USA). Western Measurements of DNA synthesis NIH/3T3 cells were grown on 24-well microtiter plates (5 Â 10 4 cells/well), serum-starved for 24 h and then treated with 10 U/ml heparin and FGF-1 or with FCS, and with SU5402 or indirubin-3 0 -monoxime as indicated, for 24 h. During the last 6 h of incubation, 1 mCi of [ 3 H]thymidine was present in the medium. Next, the cells were extracted with 5% TCA, and the radioactivity incorporated onto TCA-insoluble material was measured as described previously (Wiedlocha et al., 1994) .
Materials and methods
Materials
Measurements of protein synthesis NIH/3T3 cells were incubated with increasing amounts of indirubin-3 0 -monoxime or SU5402 overnight in DMEM. Then the cells were transferred to HEPES medium without leucine, 1 mCi/ml [ 3 H]leucine was added and the incubation was continued for 30 min at 371C. The cells were then extracted with 5% TCA for 15 min, followed by a brief wash with 5% TCA, and subsequently dissolved in 0.1 M KOH. The cellassociated TCA-insoluble radioactivity was measured as described previously (Sandvig and Olsnes, 1982) .
Microscopy NIH/3T3 cells were grown on coverslips for 24 h, then treated with 50 ng/ml FGF-1 and 10 U/ml heparin and 20 mM SU5402 or 20 mM indirubin-3 0 -monoxime overnight. The cells were fixed with 3% paraformaldehyde in PBS for 15 min at room temperature, permeabilized with 0.05% Saponin and stained with rhodamine-phalloidin (Molecular Probes, Eugene, OR, USA). The coverslips were mounted with mowiol and examined with a Leica (Wetzlar, Germany) confocal microscopy.
FGFR1 autophosphorylation assay NIH/3T3 cells were serum starved for 24 h and for additional 2 h in fresh serum-free medium. The cells were incubated with indirubin-3 0 -monoxime or SU5402 for 15 min at 371C. Then the cells were treated with 50 ng/ml FGF-1 and 10 U/ml heparin for 30 min at 371C in the presence of the testing drugs. Next, the cells were washed, scraped from the plate, transferred to Eppendorf tubes (5 Â 10 5 cells/tube) and centrifuged. Each cell pellet was lysed in 25 ml lysis buffer (50 mM NaCl, 10 mM Tris, 5 mM ethylenediaminetetraacetic acid, 0.1% SDS, 1% Triton X-100, pH 7.4, supplemented with protease and phosphatase inhibitor cocktails). After lysis, the nuclear material was removed by centrifugation. About 10 ml of the cell lysate was subjected to SDS-PAGE and western blot using antibodies to FGFR1 (as a control for the total amount of FGFR1). The second part of the cell lysate was subjected to immunoprecipitation using antibodies to FGFR1 and protein A-Sepharose and then subjected to SDS-PAGE and western blot using anti-phospho-FGFR antibodies.
EGFR autophosphorylation assay Serum-starved Hela cells (2 Â 10 5 /sample) were pretreated with increasing concentrations of indirubin-3 0 -monoxime for 15 min at 371C. Then the cells were treated with 50 ng/ml EGF for 15 min at 371C in the presence of the drug. Next, the cells were washed with ice-cold HEPES medium, lysed in SDS-sample buffer and subjected to SDS-PAGE and western blot using anti-phospho-EGFR antibodies and after membrane stripping, antibodies to EGFR.
Binding of 125
I-FGF-1 Recombinant FGF-1 was iodinated by the Iodogen method (Fraker and Speck, 1978) . The specific activity of 125 I-FGF-1 was approximately 16 000 c.p.m./ng. Confluent NIH/3T3 cells grown on 12-well microtiter plates were washed twice with icecold binding buffer (DMEM containing 50 mM HEPES, pH 7.4, 0.2% gelatin and 10 U/ml heparin). Cells were incubated with 125 I-FGF-1 and increasing concentrations of indirubin-3 0 -monoxime for 2 h at 41C, and then they were washed twice with binding buffer, twice with PBS containing 10 U/ml heparin, once with 1 M NaCl in PBS and once with HEPES medium. The cells were lysed in 0.5 M NaOH, and the solubilized radioactivity was measured using a g-counter (1261 Multigamma, LKB Wallac, Gaithersburg, MD, USA).
Binding of [
35 S]FGF-1 to heparin-Sepharose 0 -monoxime for 2 h at 41C and then washed intensively with HEPES medium containing 10 U/ ml heparin. To measure binding to cell surface receptors, the cells were then washed with 1 M NaCl in PBS and lysed at this stage. To measure endocytosis, the cells were further incubated for 3 h at 371C in the presence of indirubine-3 0 -monoxime. Then the cells were washed with HEPES medium containing 10 U/ml heparin, twice with high-salt/low pH buffer (1 M NaCl in 20 mM sodium acetate, pH 4.0), and once with HEPES medium again, and then lysed. [
35 S]FGF-1 was extracted from the cell lysates by binding to heparin-Sepharose and subjected to SDS-PAGE and fluorography.
Signaling protein phoshorylation assays NIH/3T3 cells were serum starved for 24 h and for additional 2 h in fresh serum-free medium. Then they were preincubated with indirubin-3 0 -monoxime or SU5402 for 15 min at 371C. Next, the cells were treated with 10 U/ml heparin and 50 ng/ml FGF-1 or with 10% FCS for various periods of time at 371C. After the treatment the cells were lysed in SDS sample buffer and analysed by SDS-PAGE and western blot using indicated antibodies.
Indirubin-3
0 -monoxime inhibits FGFR1 Y Zhen et al Measurement of growth of KG-1a and K562 cells KG-1a and K562 cells seeded at 2.0 Â 10 4 cells/ml were grown for 48 h at 371C in the absence or presence of indirubin-3 0 -monoxime, SU5402 and SB203580. Then the number of cells were counted using a coulter counter (Beckman Z1, Laborel, Oslo, Norway).
Abbreviations AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; FCS, fetal calf serum; FGFR, FGF receptor; HSPG, heparan sulfate proteoglycan; JNK, c-Jun N -terminal kinase; Rb, retinoblastoma protein; TCA, trichloroacetic acid.
